Biotronik announced the European market approval of the Selectra left ventricular lead delivery system for cardiac resynchronization therapy (CRT) devices.
Selectra is the first telescopic delivery system for direct delivery of low-profile left ventricular leads to incorporate a slittable haemostatic valve that reduces the complexity involved during a lead implant as well as the likelihood of moving the left ventricular lead as the sheath is removed.
The device’s unique handle design has an integrated side port, allowing for maximum flexibility and one-handed manipulation, which results in ultimate convenience during even the most challenging implantations. The superior shaft design, with its balanced stiffness segmentations, provides optimal torque transmission while preventing kinking of the catheter. The short soft tip design minimises the risk for dissections during cannulation of the coronary sinus and prolapse during lead maneuvering.
“Biotronik spent considerable time understanding electrophysiologists’ needs and examining the challenges they face with current lead delivery systems. It is this intensive insight that has formed the basis for engineering Selectra’s advanced design,” commented Marlou Janssen, vice president of Global Marketing & Sales.
“In a challenging CRT case,” Janssen continues, “there are two concerns regarding lead delivery. First, you have to ensure that you have achieved optimal lead placement, then you must be able to remove the catheter without altering the position of the lead. The Selectra system appears to be very promising in terms of balancing flexibility and firmness, which will allow easy access to the coronary sinus. Slitting the Selectra sheaths is simple and straightforward.”